- Business Wire•5 hours agoUpdated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)
Incyte Corporation today announced that the European Society for Medical Oncology has published an abstract containing updated data from the Phase 1 portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® , Merck’s anti-PD-1 therapy.
- Business Wire•yesterday
Incyte Corporation today announced that its first-in-class JAK1/JAK2 inhibitor, Jakafi® , has been included as a recommended treatment in the latest National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for myelofibrosis .
- Benzinga•2 days ago
Argus raised its price target on shares of Incyte Corporation (NASDAQ: INCY ), premising the positive opinion on a trio of factors. The firm noted that the company reported better than expected second ...
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||91.86 x 100|
|Ask||91.99 x 100|
|Day's Range||91.39 - 95.39|
|52wk Range||55.00 - 131.33|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||250.07|
|Avg Vol (3m)||1,136,500|
|Dividend & Yield||N/A (N/A)|